Durable Remission After Triple Therapy in New-Onset HFrEF

Durable remission from new-onset HFrEF can be achieved with fewer drugs than quadruple GDMT. Diagnostic tools are needed to identify such patients.

Authors

Institutions

Publication Details

Journal
JACC Case Reports
Published
2026-01-14
DOI
https://doi.org/10.1016/j.jaccas.2025.106526
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Durable Remission After Triple Therapy in New-Onset HFrEF

Jake Munch, Mark H. Drazner, Jennifer T. Thibodeau, Michael Pitonak
JACC Case Reports
Esophageal Cancer Research and Treatment
article

Durable Remission After Triple Therapy in New-Onset HFrEF

Jake Munch, Mark H. Drazner, Jennifer T. Thibodeau, Michael Pitonak
article en

Abstract

Durable remission from new-onset HFrEF can be achieved with fewer drugs than quadruple GDMT. Diagnostic tools are needed to identify such patients.

JACC Case ReportsVol. 31(7)
Southwestern Medical Center (US), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 89%
Esophageal Cancer Research and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Durable Remission After Triple Therapy in New-Onset HFrEF — Jake Munch, Mark H. Drazner, et al. · JACC Case Reports (2026) | TGRS Research Map | TGRS